Dual Targeting of Histone Methyltransferase G9a and DNA‐Methyltransferase 1 for the Treatment of Experimental Hepatocellular Carcinoma
Open accessAbstract
Epigenetic modifications such as DNA and histone methylation functionally cooperate in fostering tumor growth, including that of hepatocellular carcinoma (HCC). Pharmacological targeting of these mechanisms may open new therapeutic avenues. We aimed to determine the therapeutic efficacy and potential mechanism of action of our dual G9a histone‐methyltransferase and DNA‐methyltransferase 1 (DNMT1) inhibitor in human HCC cells and their crosstalk with fibrogenic cells. The expression of G9a and DNMT1, along with that of their molecular adaptor ubiquitin‐like with PHD and RING finger domains‐1 (UHRF1), was measured in human HCCs (n = 268), peritumoral tissues (n = 154), and HCC cell lines (n = 32). We evaluated the effect of individual and combined inhibition of G9a and DNMT1 on HCC cell growth by pharmacological and genetic approaches. The activity of our lead compound, CM‐272, was examined in HCC cells under normoxia and hypoxia, human hepatic stellate cells and LX2 cells, and xenograft tumors formed by HCC or combined HCC+LX2 cells. We found a significant and correlative overexpression of G9a, DNMT1, and UHRF1 in HCCs in association with poor prognosis. Independent G9a and DNMT1 pharmacological targeting synergistically inhibited HCC cell growth. CM‐272 potently reduced HCC and LX2 cells proliferation and quelled tumor growth, particularly in HCC+LX2 xenografts. Mechanistically, CM‐272 inhibited the metabolic adaptation of HCC cells to hypoxia and induced a differentiated phenotype in HCC and fibrogenic cells. The expression of the metabolic tumor suppressor gene fructose‐1,6‐bisphosphatase (FBP1), epigenetically repressed in HCC, was restored by CM‐272. Conclusion: Combined targeting of G9a/DNMT1 with compounds such as CM‐272 is a promising strategy for HCC treatment. Our findings also underscore the potential of differentiation therapy in HCC.
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
Other epigenetic regulators, including MECP2, EZH1/2, BRD4, SIRT1, KDM4D, and TET3, can contribute to chemically induced liver fibrosis.
“Other epigenetic regulators, such as methyl CpG binding protein 2 (MECP2), enhancer of zeste homolog 1/2 (EZH1/2), bromodomain-containing protein 4 (BRD4), Sirtuin 1 (SIRT1), lysine-specific demethylase 4D (KDM4D), and tet methylcytosine dioxygenase 3 (TET3), can contribute to chemically-induced liver fibrosis (174-178) (179, 180) (181).”
From Found in translation—Fibrosis in metabolic dysfunction–associated steatohepatitis (MASH) (2023) · cites this paper as [175]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Cites
Sorafenib in advanced hepatocellular carcinoma
Llovet, J. M., Ricci, S., Mazzaferro, V., Hilgard, P., Gane, E., Blanc, J.-F., de Oliveira, A. C., Santoro, A., Raoul, J.-L., Forner, A., et al. (2008) · New England Journal of Medicine · doi:10.1056/nejmoa0708857 · Cited by 13,097 · see citing works
El-Khoueiry, A. B., Sangro, B., Yau, T., Crocenzi, T. S., Kudo, M., Hsu, C., Kim, T.-Y., Choo, S.-P., Trojan, J., Welling, T. H., et al. (2017) · The Lancet · doi:10.1016/s0140-6736(17)31046-2 · Cited by 4,280 · see citing works
Bruix, J., Qin, S., Merle, P., Granito, A., Huang, Y., Bodoky, G., Pracht, M., Yokosuka, O., Rosmorduc, O., Breder, V. V., et al. (2016) · The Lancet · doi:10.1016/s0140-6736(16)32453-9 · Cited by 3,657 · see citing works
Understanding the Intersections between Metabolism and Cancer Biology
Heiden, M. G. V., & DeBerardinis, R. J. (2017) · Cell · doi:10.1016/j.cell.2016.12.039 · Cited by 2,316 · see citing works
TLR4 enhances TGF-β signaling and hepatic fibrosis
Seki, E., De Minicis, S., Österreicher, C. H., Kluwe, J., Osawa, Y., Brenner, D. A., & Schwabe, R. F. (2007) · Nature Medicine · doi:10.1038/nm1663 · Cited by 1,942 · see citing works
Schulze, K., Imbeaud, S., Letouzé, E., Alexandrov, L. B., Calderaro, J., Rebouissou, S., Couchy, G., Meiller, C., Shinde, J., Soysouvanh, F., et al. (2015) · Nature Genetics · doi:10.1038/ng.3252 · Cited by 1,803 · see citing works
Self-citationGenetic landscape and biomarkers of hepatocellular carcinoma
Zucman-Rossi, J., Villanueva, A., Nault, J.-C., & Llovet, J. M. (2015) · Gastroenterology · doi:10.1053/j.gastro.2015.05.061 · Cited by 1,325 · see citing works
Self-citationTranscriptome classification of HCC is related to gene alterations and to new therapeutic targets
Boyault, S., Rickman, D. S., de Reyniès, A., Balabaud, C., Rebouissou, S., Jeannot, E., Hérault, A., Saric, J., Belghiti, J., Franco, D., et al. (2007) · Hepatology · doi:10.1002/hep.21467 · Cited by 1,258 · see citing works
Self-citationHoshida, Y., Nijman, S. M. B., Kobayashi, M., Chan, J. A., Brunet, J.-P., Chiang, D. Y., Villanueva, A., Newell, P., Ikeda, K., Hashimoto, M., et al. (2009) · Cancer Research · doi:10.1158/0008-5472.can-09-1089 · Cited by 1,238 · see citing works
Reprogramming glucose metabolism in cancer: can it be exploited for cancer therapy?
Hay, N. (2016) · Nature reviews. Cancer · doi:10.1038/nrc.2016.77 · Cited by 1,124 · see citing works
DNA methylation pathways and their crosstalk with histone methylation
Du, J., Johnson, L. M., Jacobsen, S. E., & Patel, D. J. (2015) · Nature Reviews Molecular Cell Biology · doi:10.1038/nrm4043 · Cited by 1,000 · see citing works
Tan, J., Yang, X., Zhuang, L., Jiang, X., Chen, W., Lee, P. L., Karuturi, R. K. M., Tan, P. B. O., Liu, E. T., & Yu, Q. (2007) · Genes & Development · doi:10.1101/gad.1524107 · Cited by 895 · see citing works
Nault, J., Mallet, M., Pilati, C., Caldéraro, J., Bioulac‐Sage, P., Laurent, C., Laurent, A., Cherqui, D., Balabaud, C. P., & Zucman‐Rossi, J. (2013) · Nature Communications · doi:10.1038/ncomms3218 · Cited by 691 · see citing works
Self-citationRole of epithelial to mesenchymal transition in hepatocellular carcinoma
Giannelli, G., Koudelková, P., Dituri, F., & Mikulits, W. (2016) · Journal of Hepatology · doi:10.1016/j.jhep.2016.05.007 · Cited by 618 · see citing works
Fructose-1,6-bisphosphatase opposes renal carcinoma progression
Li, B., Qiu, B., Lee, D. S. M., Walton, Z. E., Ochocki, J. D., Mathew, L. K., Mancuso, A., Gade, T. P. F., Keith, B., Nissim, I., et al. (2014) · Nature · doi:10.1038/nature13557 · Cited by 535 · see citing works
A compendium of gene expression in normal human tissues
Hsiao, L., Dangond, F., Yoshida, T., Hong, R., Jensen, R. V., Misra, J., DILLON, W., LEE, K. F., Clark, K., Haverty, P. M., et al. (2001) · Physiological Genomics · doi:10.1152/physiolgenomics.00040.2001 · Cited by 503 · see citing works
Dong, C., Wu, Y., Yao, J., Wang, Y., Yu, Y., Rychahou, P. G., Evers, B. M., & Zhou, B. P. (2012) · Journal of Clinical Investigation · doi:10.1172/jci57349 · Cited by 466 · see citing works
Differentiation therapy revisited
de Thé, H. (2018) · Nature reviews. Cancer · doi:10.1038/nrc.2017.103 · Cited by 462 · see citing works
G9a/GLP complexes independently mediate H3K9 and DNA methylation to silence transcription
Tachibana, M., Matsumura, Y., Fukuda, M., Kimura, H., & Shinkai, Y. (2008) · The EMBO Journal · doi:10.1038/emboj.2008.192 · Cited by 431 · see citing works
DNA methylation‐based prognosis and epidrivers in hepatocellular carcinoma
Villanueva, A., Portela, A., Sayols, S., Battiston, C., Hoshida, Y., Méndez‐González, J., Imbeaud, S., Letouzé, É., Hernández–Gea, V., Cornellà, H., et al. (2015) · Hepatology · doi:10.1002/hep.27732 · Cited by 430 · see citing works
Self-citationAvila, M. A., Berasain, C., Torres, L., Martín‐Duce, A., Corrales, F. J., Yang, H., Prìeto, J., Lu, S. C.-L., Caballería, J., Rodés, J., et al. (2000) · Journal of Hepatology · doi:10.1016/s0168-8278(00)80122-1 · Cited by 339 · see citing works
Self-citationA Hepatocellular Carcinoma 5-Gene Score Associated With Survival of Patients After Liver Resection
Nault, J., de Reyniès, A., Villanueva, A., Caldéraro, J., Rebouissou, S., Couchy, G., Decaens, T., Franco, D., Imbeaud, S., Rousseau, F., et al. (2013) · Gastroenterology · doi:10.1053/j.gastro.2013.03.051 · Cited by 336 · see citing works
Self-citationUHRF1 Overexpression Drives DNA Hypomethylation and Hepatocellular Carcinoma
Mudbhary, R., Hoshida, Y., Chernyavskaya, Y., Jacob, V., Villanueva, A., Fiel, M. I., Chen, X., Kojima, K., Thung, S. N., Bronson, R. T., et al. (2014) · Cancer Cell · doi:10.1016/j.ccr.2014.01.003 · Cited by 310 · see citing works
Dauch, D., Rudalska, R., Cossa, G., Nault, J., Kang, T.-W., Wüestefeld, T., Hohmeyer, A., Imbeaud, S., Yevsa, T., Hoenicke, L., et al. (2016) · Nature Medicine · doi:10.1038/nm.4107 · Cited by 274 · see citing works
Self-citationSaito, Y., Kanai, Y., Nakagawa, T., Sakamoto, M., Saito, H., Ishii, H., & Hirohashi, S. (2003) · International Journal of Cancer · doi:10.1002/ijc.11127 · Cited by 259 · see citing works
Functional Role of G9a Histone Methyltransferase in Cancer
Casciello, F., Windloch, K., Gannon, F., & Lee, J. S. (2015) · Frontiers in Immunology · doi:10.3389/fimmu.2015.00487 · Cited by 253 · see citing works
Wozniak, R. J., Klimecki, W. T., Lau, S. S., Feinstein, Y., & Futscher, B. W. (2006) · Oncogene · doi:10.1038/sj.onc.1209763 · Cited by 213 · see citing works
Ferry, L., Fournier, A., Tsusaka, T., Adelmant, G., Shimazu, T., Matano, S., Kirsh, O., Amouroux, R., Dohmae, N., Suzuki, T., et al. (2017) · Molecular Cell · doi:10.1016/j.molcel.2017.07.012 · Cited by 203 · see citing works
Wilson, G. K., Tennant, D. A., & McKeating, J. A. (2014) · Journal of Hepatology · doi:10.1016/j.jhep.2014.08.025 · Cited by 201 · see citing works
Epigenetics in liver disease: from biology to therapeutics
Hardy, T., & Mann, D. A. (2016) · Gut · doi:10.1136/gutjnl-2015-311292 · Cited by 177 · see citing works
José‐Eneriz, E. S., Agirre, X., Rabal, O., Vilas‐Zornoza, A., Sánchez-Arias, J. A., Miranda, E., Ugarte, A., Roa, S., Paiva, B., de Mendoza, A. E., et al. (2017) · Nature Communications · doi:10.1038/ncomms15424 · Cited by 176 · see citing works
Self-citationRole of epigenetic aberrations in the development and progression of human hepatocellular carcinoma
Pogribny, I. P., & Rusyn, I. (2012) · Cancer Letters · doi:10.1016/j.canlet.2012.01.038 · Cited by 174 · see citing works
Wei, L., Chiu, D. K., Tsang, F. H., Law, C., Cheng, C. L., Au, S. L., Lee, J. M., Wong, C. C., Wong, C., & Wong, C. (2017) · Journal of Hepatology · doi:10.1016/j.jhep.2017.05.015 · Cited by 167 · see citing works
Hirata, H., Sugimachi, K., Komatsu, H., Ueda, M., Masuda, T., Uchi, R., Sakimura, S., Nambara, S., Saito, T., Shinden, Y., et al. (2016) · Cancer Research · doi:10.1158/0008-5472.can-15-2601 · Cited by 151 · see citing works
Stellate cells and the development of liver cancer: Therapeutic potential of targeting the stroma
Coulouarn, C., & Clément, B. (2014) · Journal of Hepatology · doi:10.1016/j.jhep.2014.02.003 · Cited by 142 · see citing works
Bitzer, M., Horger, M., Giannini, E. G., Ganten, T. M., Wörns, M., Siveke, J. T., Dollinger, M., Gerken, G., Scheulen, M. E., Wege, H., et al. (2016) · Journal of Hepatology · doi:10.1016/j.jhep.2016.02.043 · Cited by 139 · see citing works
Epigenetics and Liver Fibrosis
Morán‐Salvador, E., & Mann, J. (2017) · Cellular and Molecular Gastroenterology and Hepatology · doi:10.1016/j.jcmgh.2017.04.007 · Cited by 137 · see citing works
G9a drives hypoxia-mediated gene repression for breast cancer cell survival and tumorigenesis
Casciello, F., Al‐Ejeh, F., Kelly, G., Brennan, D. J., Ngiow, S. F., Young, A., Stoll, T. M., Windloch, K., Hill, M. M. C., Smyth, M. J., et al. (2017) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1618706114 · Cited by 136 · see citing works
Gut roundtable meeting paper: selected recent advances in hepatocellular carcinoma
Gerbes, A. L., Zoulim, F., Tilg, H., Dufour, J., Bruix, J., Paradis, V., Salem, R., Peck‐Radosavljevic, M., Galle, P. R., Greten, T. F., et al. (2017) · Gut · doi:10.1136/gutjnl-2017-315068 · Cited by 127 · see citing works
Kluwe, J., Wongsiriroj, N., Troeger, J. S., Gwak, G., Dapito, D. H., Pradère, J., Jiang, H., Siddiqi, M., Piantedosi, R., O’Byrne, S. M., et al. (2011) · Gut · doi:10.1136/gut.2010.209551 · Cited by 121 · see citing works
Chiba, T., Saito, T., Yuki, K., Zen, Y., Koide, S., Kanogawa, N., Motoyama, T., Ogasawara, S., Suzuki, E., Ooka, Y., et al. (2014) · International Journal of Cancer · doi:10.1002/ijc.28985 · Cited by 117 · see citing works
Giannelli, G., Rani, B., Dituri, F., Cao, Y., & Palasciano, G. (2014) · Gut · doi:10.1136/gutjnl-2014-307323 · Cited by 109 · see citing works
Role of Hypoxia-Inducible Factors in the Development of Liver Fibrosis
Roth, K., & Copple, B. L. (2015) · Cellular and Molecular Gastroenterology and Hepatology · doi:10.1016/j.jcmgh.2015.09.005 · Cited by 90 · see citing works
Rebouissou, S., Bella, T. L., Rekik, S., Imbeaud, S., Calatayud, A.-L., Rohr‐Udilova, N., Martin, Y., Couchy, G., Bioulac‐Sage, P., Grasl‐Kraupp, B., et al. (2017) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-16-3118 · Cited by 64 · see citing works
Self-citationRecruitment of coregulator G9a by Runx2 for selective enhancement or suppression of transcription
Purcell, D. J., Khalid, O. S., Ou, C. Y., Little, G. H., Frenkel, B., Baniwal, S. K., & Stallcup, M. R. (2012) · Journal of Cellular Biochemistry · doi:10.1002/jcb.24114 · Cited by 55 · see citing works
Jiang, Y., Wang, S., Zhao, Y., Lin, C., Zhong, F., Li, J., He, F., & Wang, H. (2015) · The FASEB Journal · doi:10.1096/fj.14-251751 · Cited by 48 · see citing works
Genomic landscape of liver cancer
Zhang, Z. (2012) · Nature Genetics · doi:10.1038/ng.2412 · Cited by 45 · see citing works
Transcriptional Regulation of Serine/Threonine Kinase-15 (STK15) Expression by Hypoxia and HIF-1
Klein, A. M., Flügel, D., & Kietzmann, T. (2008) · Molecular Biology of the Cell · doi:10.1091/mbc.e08-01-0042 · Cited by 42 · see citing works
Huidobro, C., Toraño, E. G., Fernández, A. F., Urdinguio, R. G., Rodríguez, R. M., Ferrero, C., Martínez‐Camblor, P., Boix, L., Bruix, J., García‐Rodríguez, J. L., et al. (2013) · Journal of Molecular Medicine · doi:10.1007/s00109-013-1010-8 · Cited by 37 · see citing works
Rombouts, K., & Carloni, V. (2015) · Methods in molecular biology · doi:10.1007/978-1-4939-3170-5_17 · Cited by 19 · see citing works
Self-citation
Flagged first, then by citations
Cited by
Sorted by citations
Hepatocellular carcinoma: signaling pathways and therapeutic advances
Zheng, J., Wang, S., Xia, L., Sun, Z., Chan, K. M., Bernards, R., Qin, W., Chen, J., Xia, Q., & Jin, H. (2025) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-024-02075-w · Cited by 387 · see citing works
Epigenetics in hepatocellular carcinoma
Nagaraju, G. P., Dariya, B., Kasa, P., Peela, S., & El‐Rayes, B. F. (2021) · Seminars in Cancer Biology · doi:10.1016/j.semcancer.2021.07.017 · Cited by 346 · see citing works
Gluconeogenesis in Cancer: Function and Regulation of PEPCK, FBPase, and G6Pase
Wang, Z., & Dong, C. (2018) · Trends in cancer · doi:10.1016/j.trecan.2018.11.003 · Cited by 294 · see citing works
Inhibition of a G9a/DNMT network triggers immune-mediated bladder cancer regression
Segovia, C., José‐Eneriz, E. S., Munera-Maravilla, E., Martínez‐Fernández, M., Gárate, L., Miranda, E., Vilas‐Zornoza, A., Lodewijk, I., Rubio, C., Segrelles, C., et al. (2019) · Nature Medicine · doi:10.1038/s41591-019-0499-y · Cited by 188 · see citing works
Self-citationKong, X., Chen, J., Xie, W., Brown, S. M., Cai, Y., Wu, K., Fan, D., Nie, Y., Yegnasubramanian, S., Tiedemann, R. L., et al. (2019) · Cancer Cell · doi:10.1016/j.ccell.2019.03.003 · Cited by 163 · see citing works
Found in translation—Fibrosis in metabolic dysfunction–associated steatohepatitis (MASH)
Wang, S., & Friedman, S. L. (2023) · Science Translational Medicine · doi:10.1126/scitranslmed.adi0759 · Cited by 158 · see citing works
Recent progress in DNA methyltransferase inhibitors as anticancer agents
Zhang, Z., Wang, G., Li, Y., Lei, D., Xiang, J., Ouyang, L., Wang, Y., & Yang, J. (2022) · Frontiers in Pharmacology · doi:10.3389/fphar.2022.1072651 · Cited by 149 · see citing works
Chen, Y., Ren, B., Yang, J., Wang, H., Yang, G., Xu, R., You, L., & Zhao, Y. (2020) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-020-00252-1 · Cited by 143 · see citing works
Exploiting RIG-I-like receptor pathway for cancer immunotherapy
Jiang, Y., Zhang, H., Wang, J., Chen, J., Guo, Z., Liu, Y., & Hua, H. M. (2023) · Journal of Hematology & Oncology · doi:10.1186/s13045-023-01405-9 · Cited by 143 · see citing works
Llópiz, D., Ruiz, M., Villanueva, L., Iglesias, T., Silva, L., Egea, J., Lasarte, J. J., Pivette, P., Trochon-Joseph, V., Vasseur, B., et al. (2018) · Cancer Immunology Immunotherapy · doi:10.1007/s00262-018-2283-0 · Cited by 137 · see citing works
Epigenetics in hepatocellular carcinoma development and therapy: The tip of the iceberg
Fernández-Barrena, M. G., Arechederra, M., Colyn, L., Berasain, C., & Avila, M. A. (2020) · JHEP Reports · doi:10.1016/j.jhepr.2020.100167 · Cited by 126 · see citing works
Self-citationRecent progress in histone methyltransferase (G9a) inhibitors as anticancer agents
Cao, H., Li, L., Yang, D., Zeng, L., Xie, Y., Yu, B., Liao, G., & Chen, J. (2019) · European Journal of Medicinal Chemistry · doi:10.1016/j.ejmech.2019.06.072 · Cited by 112 · see citing works
Bárcena‐Varela, M., Paish, H. L., Alvarez, L., Uriarte, I., Latasa, M. U., Santamaría, E., Recalde, M., Garate, M., Clavería-Cabello, A., Colyn, L., et al. (2020) · Gut · doi:10.1136/gutjnl-2019-320205 · Cited by 96 · see citing works
Self-citationEpigenetic remodelling in human hepatocellular carcinoma
Braghini, M. R., Re, O. L., Romito, I., Fernández‐Barrena, M. G., Barbaro, B., Pomella, S., Rota, R., Vinciguerra, M., Avila, M. A., & Alisi, A. (2022) · Journal of Experimental & Clinical Cancer Research · doi:10.1186/s13046-022-02297-2 · Cited by 88 · see citing works
Self-citationEHMT1/EHMT2 in EMT, cancer stemness and drug resistance: emerging evidence and mechanisms
Nachiyappan, A., Gupta, N., & Taneja, R. (2021) · FEBS Journal · doi:10.1111/febs.16334 · Cited by 77 · see citing works
Yan, M., Cui, Y., & Xiang, Q. (2025) · Theranostics · doi:10.7150/thno.106597 · Cited by 76 · see citing works
Intrahepatic recurrence of hepatocellular carcinoma after resection: an update
Tampaki, M., Papatheodoridis, G., & Cholongitas, Ε. (2021) · Clinical Journal of Gastroenterology · doi:10.1007/s12328-021-01394-7 · Cited by 73 · see citing works
Epigenetic Mechanisms in Hepatic Stellate Cell Activation During Liver Fibrosis and Carcinogenesis
Bárcena‐Varela, M., Colyn, L., & Fernández‐Barrena, M. G. (2019) · International Journal of Molecular Sciences · doi:10.3390/ijms20102507 · Cited by 72 · see citing works
Self-citationDNA Methylation as a Therapeutic Target for Bladder Cancer
Nunes, S. P., Henrique, R., Jerónimo, C., & Paramio, J. M. (2020) · Cells · doi:10.3390/cells9081850 · Cited by 71 · see citing works
Dual inhibitors of DNMT and HDAC induce viral mimicry to induce antitumour immunity in breast cancer
Huang, W., Zhu, Q., Shi, Z., Tu, Y., Li, Q., Zheng, W., Yuan, Z., Li, L., Zu, X., Hao, Y., et al. (2024) · Cell Death Discovery · doi:10.1038/s41420-024-01895-7 · Cited by 71 · see citing works
Lin, H., Jeon, A., Chen, K., Lee, C. J. M., Wu, L., Chong, S.-L., Anene-Nzelu, C. G., Foo, R., & Chow, P. K. H. (2025) · British Journal of Cancer · doi:10.1038/s41416-025-02969-8 · Cited by 65 · see citing works
Yang, Y., Zhang, G., Guo, F., Li, Q., Luo, H. B., Shu, Y., Shen, Y., Gan, J., Xu, L., & Yang, H. (2020) · Cell Reports · doi:10.1016/j.celrep.2020.108340 · Cited by 64 · see citing works
Colyn, L., Bárcena‐Varela, M., Álvarez‐Sola, G., Latasa, M. U., Uriarte, I., Santamaría, E., Herranz, J. M., Santos‐Laso, Á., Arechederra, M., de Gauna, M. R., et al. (2020) · Hepatology · doi:10.1002/hep.31642 · Cited by 62 · see citing works
Self-citationEpigenetic Mechanisms in Gastric Cancer: Potential New Therapeutic Opportunities
Canale, M., Gardini, A. C., Ulivi, P., Arechederra, M., Berasain, C., Lollini, P., Fernández‐Barrena, M. G., & Avila, M. A. (2020) · International Journal of Molecular Sciences · doi:10.3390/ijms21155500 · Cited by 59 · see citing works
Self-citationAseem, S. O., Jalan‐Sakrikar, N., Chi, C., Navarro‐Corcuera, A., de Assuncao, T. M., Hamdan, F. H., Chowdhury, S. A., Bañales, J. M., Johnsen, S. A., Shah, V. H., et al. (2020) · Gastroenterology · doi:10.1053/j.gastro.2020.10.008 · Cited by 57 · see citing works
Liu, Y., Sun, Y., Yang, J., Wu, D., Yu, S., Liu, J., Hu, T., Luo, J., & Zhou, H. (2024) · Molecular Cancer · doi:10.1186/s12943-024-01993-1 · Cited by 57 · see citing works
Arora, I., & Tollefsbol, T. O. (2020) · Methods · doi:10.1016/j.ymeth.2020.09.008 · Cited by 56 · see citing works
Identification and experimental validation of druggable epigenetic targets in hepatoblastoma
Clavería-Cabello, A., Herranz, J. M., Latasa, M. U., Arechederra, M., Uriarte, I., Pineda‐Lucena, A., Prósper, F., Berraondo, P., Alonso, C., Sangro, B., et al. (2023) · Journal of Hepatology · doi:10.1016/j.jhep.2023.05.031 · Cited by 55 · see citing works
Self-citationStructure, Activity, and Function of the Protein Lysine Methyltransferase G9a
Poulard, C., Noureddine, L. M., Pruvost, L., & Romancer, M. L. (2021) · Life · doi:10.3390/life11101082 · Cited by 54 · see citing works
Molecular cross-talk between Y5-receptor and neuropeptide Y drives liver cancer
Dietrich, P., Wormser, L., Fritz, V., Seitz, T., de Maria, M., Schambony, A., Kremer, A., Günther, C., Itzel, T., Thasler, W., et al. (2020) · Zeitschrift für Gastroenterologie - German Journal of Gastroenterology · doi:10.1172/jci131919 · Cited by 40 · see citing works
Epigenetic Biomarkers for the Diagnosis and Treatment of Liver Disease
Arechederra, M., Recalde, M., Gárate‐Rascón, M., Fernández‐Barrena, M. G., Avila, M. A., & Berasain, C. (2021) · Cancers · doi:10.3390/cancers13061265 · Cited by 53 · see citing works
Self-citationGarcia-Gomez, A., Li, T., de la Calle-Fabregat, C., Rodríguez-Ubreva, J., Ciudad, L., Català-Moll, F., Godoy-Tena, G., Martín-Sánchez, M., San-Segundo, L., Muntión, S., et al. (2021) · Nature Communications · doi:10.1038/s41467-020-20715-x · Cited by 57 · see citing works
Self-citationOura, K., Morishita, A., Hamaya, S., Fujita, K., & Masaki, T. (2023) · International Journal of Molecular Sciences · doi:10.3390/ijms24032805 · Cited by 50 · see citing works
Nanodiamond-Mediated Delivery of a G9a Inhibitor for Hepatocellular Carcinoma Therapy
Gu, M., Toh, T. B., Hooi, L., Lim, J. J., Zhang, X., & Chow, E. K. (2019) · ACS Applied Materials & Interfaces · doi:10.1021/acsami.9b16323 · Cited by 48 · see citing works
Tao, S., Liang, S., Zeng, T., & Yin, D. (2023) · Frontiers in Immunology · doi:10.3389/fimmu.2022.1043667 · Cited by 46 · see citing works
Rahman, Z., Bazaz, M. R., Devabattula, G., Khan, M. A., & Godugu, C. (2020) · Journal of Biochemical and Molecular Toxicology · doi:10.1002/jbt.22674 · Cited by 40 · see citing works
Fang, T., Jiao, Z., You, Y., Cao, J., Wang, C., Liu, J., & Zhao, W. (2023) · Biochemical Pharmacology · doi:10.1016/j.bcp.2023.115489 · Cited by 40 · see citing works
Inhibition of DNMT1 potentiates antitumor immunity in oral squamous cell carcinoma
Yang, S., Wang, W., Zhou, J., Wu, L., Zhang, M.-J., Yang, Q., Deng, W., & Sun, Z. (2022) · International Immunopharmacology · doi:10.1016/j.intimp.2022.109113 · Cited by 40 · see citing works
Hepatocellular Carcinoma: Updates in Pathogenesis, Detection and Treatment
Martínez‐Chantar, M. L., Avila, M. A., & Lu, S. C.-L. (2020) · Cancers · doi:10.3390/cancers12102729 · Cited by 37 · see citing works
Insights for the Design of Protein Lysine Methyltransferase G9a Inhibitors
Mariasoosai, C., Dhayalan, A., Hsieh, H., & Coumar, M. S. (2019) · Future Medicinal Chemistry · doi:10.4155/fmc-2018-0396 · Cited by 36 · see citing works
SMYD2 promotes cervical cancer growth by stimulating cell proliferation
Sun, J., Li, H., Ma, H., Shi, Y., Yin, L.-R., & Guo, S. (2019) · Cell & Bioscience · doi:10.1186/s13578-019-0340-9 · Cited by 33 · see citing works
Nakatsuka, T., Tateishi, K., Kato, H., Fujiwara, H., Yamamoto, K., Kudo, Y., Nakagawa, H., Tanaka, Y., Ijichi, H., Ikenoue, T., et al. (2021) · Cell Death and Disease · doi:10.1038/s41419-020-03381-1 · Cited by 29 · see citing works
Li, A., Wang, R., Zhao, Y. Q., Zhao, P., & Yang, J. (2024) · Metabolites · doi:10.3390/metabo14060325 · Cited by 28 · see citing works
Thanapirom, K., Caon, E., Papatheodoridi, Μ., Frenguelli, L., Al‐Akkad, W., Zhenzhen, Z., Vilia, M. G., Pinzani, M., Mazza, G., & Rombouts, K. (2021) · Cancers · doi:10.3390/cancers13194936 · Cited by 28 · see citing works
Self-citationDevelopments in predictive biomarkers for hepatocellular carcinoma therapy
Gardini, A. C., Orsi, G., Caputo, F., & Ercolani, G. (2020) · Expert Review of Anticancer Therapy · doi:10.1080/14737140.2020.1712198 · Cited by 28 · see citing works
Epigenetic mechanisms involved in hepatocellular carcinoma development and progression
Bueloni, B., Fernández‐Barrena, M. G., Avila, M. A., Bayo, J., & Mazzolini, G. D. (2025) · eGastroenterology · doi:10.1136/egastro-2025-100186 · Cited by 27 · see citing works
Self-citationGolonka, R., & Vijay-Kumar, M. (2021) · Advances in Cancer Research · doi:10.1016/bs.acr.2020.10.004 · Cited by 21 · see citing works
Role of long non‑coding RNAs and related epigenetic mechanisms in liver fibrosis (Review)
Ganguly, N., & Chakrabarti, S. (2021) · International Journal of Molecular Medicine · doi:10.3892/ijmm.2021.4856 · Cited by 27 · see citing works
Liu, Y., Cheng, H., Cheng, C., Zheng, F., Zhao, Z., Chen, Q., Zeng, W., Zhang, P., Huang, C., Jiang, W., et al. (2022) · Cancer Medicine · doi:10.1002/cam4.4535 · Cited by 26 · see citing works
Thymoquinone Is a Multitarget Single Epidrug That Inhibits the UHRF1 Protein Complex
Abdullah, O., Omran, Z., Hosawi, S. B. I., Hamiche, A., Bronner, C., & Alhosin, M. (2021) · Genes · doi:10.3390/genes12050622 · Cited by 26 · see citing works
He, Y., Hua, R., Li, B., Gu, H., Sun, Y., & Li, Z. (2020) · Aging · doi:10.18632/aging.103916 · Cited by 25 · see citing works
Yuan, L.-T., Lee, W.-J., Yang, Y., Chen, B.-R., Yang, C., Chen, M.-W., Chen, J., Hsiao, M., Chien, M., & Hua, K. (2021) · Cancers · doi:10.3390/cancers13102376 · Cited by 25 · see citing works
López‐López, E., Rabal, O., Oyarzábal, J., & Medina‐Franco, J. L. (2020) · Journal of Computer-Aided Molecular Design · doi:10.1007/s10822-020-00298-x · Cited by 25 · see citing works
Self-citationLiu, W. H., Miner, R. E., Albaugh, B. N., Ananiev, G. E., Wildman, S. A., & Denu, J. M. (2022) · Biochemistry · doi:10.1021/acs.biochem.1c00698 · Cited by 24 · see citing works
Cai, J., Wang, J., Jiang, C., Ye, L., He, X., Huang, J., Sun, X. Y., Ren, Z., Lai, X., Qiu, Y., et al. (2023) · Journal of Hepatology · doi:10.1016/j.jhep.2023.08.007 · Cited by 24 · see citing works
Thng, D. K. H., Hooi, L., Toh, C. C. M., Lim, J. J., Rajagopalan, D., Syariff, I. Q. C., Tan, Z. M., Rashid, M. B. M. A., Zhou, L., Kow, A. W. C., et al. (2023) · Molecular Oncology · doi:10.1002/1878-0261.13417 · Cited by 23 · see citing works
Chen, S., Zhang, W., Li, X., Cao, Z., & Liu, C. (2024) · Cell Death and Disease · doi:10.1038/s41419-024-06462-7 · Cited by 21 · see citing works
Oyón, D., López-Pascual, A., Castelló-Uribe, B., Uriarte, I., Orsi, G., Llorente, S., Elurbide, J., Adán-Villaescusa, E., Valbuena-Goiricelaya, E., Irigaray-Miramon, A., et al. (2025) · Journal of Experimental & Clinical Cancer Research · doi:10.1186/s13046-024-03268-5 · Cited by 21 · see citing works
Self-citationEpigenetic Drugs and Their Immune Modulating Potential in Cancers
Liang, Y., & Turcan, Ş. (2022) · Biomedicines · doi:10.3390/biomedicines10020211 · Cited by 19 · see citing works
DNA methylation in cell plasticity and malignant transformation in liver diseases
Kim, M., Delgado, E. R., & Ko, S. (2022) · Pharmacology & Therapeutics · doi:10.1016/j.pharmthera.2022.108334 · Cited by 20 · see citing works
Moreira‐Silva, F., Outeiro-Pinho, G., Lobo, J., Guimarães, R., Gaspar, V. M., Mano, J. F., Agirre, X., Pineda‐Lucena, A., Prósper, F., Paramio, J. M., et al. (2022) · Biomedicine & Pharmacotherapy · doi:10.1016/j.biopha.2022.113031 · Cited by 18 · see citing works
Self-citationTargeting G9a/DNMT1 methyltransferase activity impedes IGF2-mediated survival in hepatoblastoma
Demir, S., Razizadeh, N., Indersie, É., Branchereau, S., Cairo, S., & Kappler, R. (2024) · Hepatology Communications · doi:10.1097/hc9.0000000000000378 · Cited by 18 · see citing works
Hepigenetics: A Review of Epigenetic Modulators and Potential Therapies in Hepatocellular Carcinoma
Yousef, M. H., El‐Fawal, H. A. N., & Abdelnaser, A. (2020) · BioMed Research International · doi:10.1155/2020/9593254 · Cited by 18 · see citing works
Interplay Between Glucose Metabolism and Chromatin Modifications in Cancer
Ma, R., Wu, Y., Li, S., & Yu, X. (2021) · Frontiers in Cell and Developmental Biology · doi:10.3389/fcell.2021.654337 · Cited by 18 · see citing works
UHRF1 plays an oncogenic role in small cell lung cancer
Hou, J., Li, W., Zhang, S., Tan, D., Lv, K., Zhu, Y., Hou, Y., Guo, H., & Jiang, L. (2022) · Molecular Carcinogenesis · doi:10.1002/mc.23493 · Cited by 17 · see citing works
Metabolism-Associated Epigenetic and Immunoepigenetic Reprogramming in Liver Cancer
Fan, C., Kam, S., & Ramadori, P. (2021) · Cancers · doi:10.3390/cancers13205250 · Cited by 17 · see citing works
Wali, A. F., Ansari, A. R., Mir, P. A., El‐Tanani, M., Babiker, R. A., Hussain, M. S., Uppal, J., Zargar, A. I., & Mir, R. H. (2025) · Pharmaceuticals · doi:10.3390/ph18091281 · Cited by 16 · see citing works
Expósito, F., Redrado, M., Serrano, D., Fariñas, S. C., Bao‐Caamano, A., Gallach, S., Lewintre, E. J., Díaz‐Lagares, Á., Rodríguez‐Casanova, A., Sandoval, J., et al. (2024) · Cell Death and Disease · doi:10.1038/s41419-024-07156-w · Cited by 16 · see citing works
Self-citationClavería-Cabello, A., Colyn, L., Uriarte, I., Latasa, M. U., Arechederra, M., Herranz, J. M., Alvarez, L., Urmán, J., Martínez‐Chantar, M. L., Bañales, J. M., et al. (2020) · Cancers · doi:10.3390/cancers12123748 · Cited by 15 · see citing works
Self-citationCross-talk Between Histone and DNA Methylation Mediates Bone Loss in Hind Limb Unloading
Li, B., Zhao, J., Ma, J., Chen, W., Zhou, C., Wei, W., Li, S., Li, G., Xin, G., Zhang, Y., et al. (2020) · Journal of Bone and Mineral Research · doi:10.1002/jbmr.4253 · Cited by 15 · see citing works
Bellver-Sanchis, A., Ribalta-Vilella, M., Irisarri, A., Gehlot, P., Choudhary, B., Jana, A., Vyas, V. K., Banerjee, D., Pallás, M., Guerrero, A., et al. (2025) · Medicinal research reviews (Print) · doi:10.1002/med.22096 · Cited by 11 · see citing works
Wang, J. (2021) · Cancer Biology and Medicine · doi:10.20892/j.issn.2095-3941.2020.0371 · Cited by 14 · see citing works
Epigenetic regulation of IncRNA KCNKI5-ASI in gastric cancer
Zhang, H., Zhang, Z., & Wang, D. (2019) · Cancer Management and Research · doi:10.2147/cmar.s186002 · Cited by 14 · see citing works
Carotti, S., Zingariello, M., Francesconi, M. A., D’Andrea, L., Latasa, M. U., Colyn, L., Fernández‐Barrena, M. G., Flammia, R. S., Falchi, M., Righi, D., et al. (2021) · Oncogene · doi:10.1038/s41388-021-01824-3 · Cited by 13 · see citing works
Self-citationThe splicing regulator SLU7 is required to preserve DNMT1 protein stability and DNA methylation
Recalde, M., Gárate‐Rascón, M., Elizalde, M., Azkona, M., Latasa, M. U., Bárcena‐Varela, M., Sangro, B., Fernández‐Barrena, M. G., Avila, M. A., Arechederra, M., et al. (2021) · Nucleic Acids Research · doi:10.1093/nar/gkab649 · Cited by 11 · see citing works
Self-citationBeck, L. D., Awad, R. M., Basso, V., Casares, N., Ridder, K. D., Vlaeminck, Y. D., Gnata, A., Goyvaerts, C., Lecocq, Q., José‐Eneriz, E. S., et al. (2022) · Frontiers in Immunology · doi:10.3389/fimmu.2022.799636 · Cited by 12 · see citing works
Self-citationResearch advances on epigenetics and cancer metabolism
Han, H., Feng, F., & Li, H. (2021) · Journal of Zhejiang University (Medical Sciences) · doi:10.3724/zdxbyxb-2021-0053 · Cited by 12 · see citing works
Kong, M., Wu, J., Fan, Z., Chen, B., Wu, T., & Xu, Y. (2019) · Biochemical and Biophysical Research Communications · doi:10.1016/j.bbrc.2019.04.105 · Cited by 12 · see citing works
Expression landscape of epigenetic genes in human hepatocellular carcinoma
Castelló-Uribe, B., López-Pascual, A., Elurbide, J., Adán-Villaescusa, E., Valbuena-Goiricelaya, E., Martínez‐Pérez, L. A., Uriarte, I., Latasa, M. U., Sangro, B., Arechederra, M., et al. (2025) · Journal of Physiology and Biochemistry · doi:10.1007/s13105-025-01095-6 · Cited by 11 · see citing works
Self-citationEpigenetic mechanisms in HCC immune landscape: Therapeutic implications
Fernández‐Barrena, M. G., Uriarte, I., Sarobe, P., & Avila, M. A. (2025) · Seminars in Immunology · doi:10.1016/j.smim.2025.101980 · Cited by 14 · see citing works
Self-citationG9a/GLP Modulators: Inhibitors to Degraders
Mukherjee, A., & Suzuki, T. (2025) · Journal of Medicinal Chemistry · doi:10.1021/acs.jmedchem.4c02474 · Cited by 11 · see citing works
Decoding the Epigenome of Breast Cancer
Cortellesi, E., Savini, I., Veneziano, M., Gambacurta, A., Catani, M. V., & Gasperi, V. (2025) · International Journal of Molecular Sciences · doi:10.3390/ijms26062605 · Cited by 11 · see citing works
Recalde, M., Gárate-Rascón, M., Herranz, J. M., Elizalde, M., Azkona, M., Unfried, J. P., Boix, L., Reig, M., Sangro, B., Fernández-Barrena, M. G., et al. (2022) · Cancers · doi:10.3390/cancers14092048 · Cited by 14 · see citing works
Self-citationThe Future of Epigenetics: Emerging Technologies and Clinical Applications
Iyer, K. A., Tenchov, R., Sasso, J. M., Thite, T., Deng, Y., & Zhou, Q. A. (2026) · ACS Pharmacology & Translational Science · doi:10.1021/acsptsci.5c00729 · Cited by 11 · see citing works
Ding, M., Dai, X., Yang, C., Zhang, Z., Wang, Z., Wang, Y., Li, Y., & Yan, F. (2024) · Nano Letters · doi:10.1021/acs.nanolett.4c04264 · Cited by 10 · see citing works
Yang, C., Zhu, H., Tan, Y., Zhu, R., Wu, X., Li, Y., & Wang, C. (2021) · Current Cancer Drug Targets · doi:10.2174/1568009621666210618164300 · Cited by 10 · see citing works
Yang, Y., Zhou, Z., Wang, L., Gao, P., & Wu, Z. (2023) · Biochimica et Biophysica Acta (BBA) - General Subjects · doi:10.1016/j.bbagen.2023.130417 · Cited by 10 · see citing works
Uriarte, I., Santamaría, E., López-Pascual, A., Monte, M. J., Argemí, J., Latasa, M. U., Adán-Villaescusa, E., Irigaray-Miramon, A., Herranz, J. M., Arechederra, M., et al. (2024) · Biochimica et Biophysica Acta (BBA) - Molecular Basis of Disease · doi:10.1016/j.bbadis.2024.167166 · Cited by 9 · see citing works
Self-citationEpigenetic mechanisms of liver tumor resistance to immunotherapy
Sanceau, J., & Gougèlet, A. (2021) · World Journal of Hepatology · doi:10.4254/wjh.v13.i9.979 · Cited by 9 · see citing works
Song, Q., Sui, J., Yang, Y., Zhang, H., Li, Y., & Yang, L. (2025) · International Journal of Biological Macromolecules · doi:10.1016/j.ijbiomac.2024.139273 · Cited by 9 · see citing works
Epigenetic Modifications in HBV ‐Related Hepatocellular Carcinoma
Tan, X., Xun, L., Yin, Q., Chen, C., Zhang, T., & Shen, T. (2025) · Journal of Viral Hepatitis · doi:10.1111/jvh.14044 · Cited by 7 · see citing works
Senent, Y., Fresquet, V. J., Jiménez, V., Valencia, K., Expósito, F., Martín‐Úriz, P. S., Camps, G., Fernández-Pierola, E., de Córdoba, B. R., González-Huarriz, M., et al. (2025) · Molecular Cancer · doi:10.1186/s12943-025-02352-4 · Cited by 8 · see citing works
Self-citationWang, C., Wang, H., Wang, C., Tian, T., Jin, A., Liu, Y., Huo, R., Liu, T., Pan, B., Guo, W., et al. (2025) · MedComm · doi:10.1002/mco2.70312 · Cited by 7 · see citing works
Epigenetic therapies in hepatocellular carcinoma: emerging clinical tools and applications
Bueloni, B., Fernández‐Barrena, M. G., Fiore, E. J., Avila, M. A., Bayo, J., & Mazzolini, G. D. (2025) · Gut · doi:10.1136/gutjnl-2025-336317 · Cited by 7 · see citing works
Self-citationGarbuzenko, D. V. (2024) · Gene Expression · doi:10.14218/ge.2023.00090 · Cited by 6 · see citing works
Pan, Z., Seto, W., Liu, C., Mao, Y., Alqahtani, S. A., & Eslam, M. (2024) · HepatoBiliary Surgery and Nutrition · doi:10.21037/hbsn-23-562 · Cited by 7 · see citing works
Impact of CYLD on chromatin structure and histone methylation in malignant melanoma
Schott, M., Kappelmann‐Fenzl, M., Fischer, S., Fernández‐Barrena, M. G., Pineda‐Lucena, A., Avila, M. A., Kuphal, S., & Bosserhoff, A. (2022) · International Journal of Molecular Medicine · doi:10.3892/ijmm.2022.5122 · Cited by 6 · see citing works
Self-citationTranslating G9a epigenetics’ role: From cell machinery to cancer therapy
Moreira‐Silva, F., Macedo‐Silva, C., Jerónimo, C., & Julio, M. K. (2025) · Gene · doi:10.1016/j.gene.2025.149681 · Cited by 5 · see citing works
Wang, Y., Wang, J., & Ren, G. (2025) · BMC Cancer · doi:10.1186/s12885-025-15091-y · Cited by 4 · see citing works
HNF4α as a Master Regulator of Epigenetic Dynamics in Epithelial Cells
Amicone, L., Cicchini, C., & Marchetti, A. (2025) · Genes · doi:10.3390/genes17010041 · Cited by 3 · see citing works
- Authors
- Bárcena‐Varela, M., Caruso, S., Llerena, S., Álvarez‐Sola, G., Uriarte, I., Latasa, M. U., Urtasun, R., Rebouissou, S., Alvarez, L., Jimenez, M., Santamaría, E., Rodriguez‐Ortigosa, C., Mazza, G., Rombouts, K., San José‐Eneriz, E., Rabal, O., Agirre, X., Iraburu, M., Santos‐Laso, A., Banales, J. M., Zucman‐Rossi, J., Prósper, F., Oyarzabal, J., Berasain, C., Ávila, M. A., & Fernández‐Barrena, M. G.
- Affiliations
- Centro de Investigación Médica Aplicada (ES)
- Inserm (FR)
- Instituto de Salud Carlos III (ES)
- Hepatology Program,Cima‐University of Navarra,Pamplona,Spain
- University College London (GB)
- Oncohematology Program,Cima‐University of Navarra,Pamplona,Spain
- Navarre Institute of Health Research (ES)
- Department of Biochemistry and Genetics,University of Navarra,Pamplona,Spain
- CIBERehd,Instituto de Salud Carlos III,Madrid,Spain
- Molecular Therapeutics Program,Cima‐University of Navarra,Pamplona,Spain
- Corresponding author
- Berasain, Carmen
- Fernández‐Barrena, Maite G.
- ORCID
- Venue
- Hepatology
- Published
- 2019-01-04
- Volume
- 69
- Issue
- 2
- Pages
- 587-603
- ISSN
- 0270-9139 (ISSN-L)
- 1527-3350
- OpenAlex
- W2883824376
- Cited by
- 130
- References
- 50
- Citations by year
- 2026: 12 · 2025: 25 · 2024: 12 · 2023: 13 · 2022: 15 · 2021: 21 · 2020: 20 · 2019: 10 · 2018: 2
- FWCI
- 4.80
- Type
- journal article
- Language
- en
- Open access
- green
- discovery.ucl.ac.uk
- Licence
- Locations
- Hepatology (publishedVersion)
- PubMed (publishedVersion)
- UCL Discovery (University College London) (submittedVersion)
- Academica-e (Universidad Pública de Navarra) (submittedVersion)
- Funders
- Fundación Eugenio Rodríguez Pascual
- Fondation Mérieux
- Instituto de Salud Carlos III (CON14/00129, 10.13039/501100004587, PI15/01132)
- Topics
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Epigenetics and DNA Methylation
- Health Sciences › Medicine › Hepatology › Hepatocellular Carcinoma Treatment and Prognosis
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Cancer-related gene regulation
- Keywords
- hepatocellular carcinoma, G9a, histone methyltransferase, DNMT1, DNA methyltransferases, UHRF1, hepatic stellate cells, hypoxia, cancer metabolism, fructose-1,6-bisphosphatase, FBP1, differentiation therapy, tumor growth inhibition, tumor xenografts
- MeSH terms
- DNA (Cytosine-5-)-Methyltransferase 1, Animals, Antineoplastic Agents, Dogs, Carcinoma, Hepatocellular, Humans, Liver Neoplasms, Experimental, Male, Mice, Nude, Histone-Lysine N-Methyltransferase, CCAAT-Enhancer-Binding Proteins, Xenograft Model Antitumor Assays, Ubiquitin-Protein Ligases, Hep G2 Cells, Madin Darby Canine Kidney Cells
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
